Project Grant R01CA300666
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $692K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60637, USA
Similar Awards
- The National Cancer Institute awarded Northwestern University $1,297,466 under Project Grant R01CA303254 on August 12, 2026, to develop nanoscale spectroscopy methods for early colorectal cancer detection and phenotypic analysis through the Cancer Detection and Diagnosis Research program (CFDA 93.394). The project addresses the limitations of current non-endoscopic colorectal cancer screening tests by integrating three innovations: leveraging field carcinogenesis—the histologically normal,...
- The National Cancer Institute awarded the University of Southern California $699,303 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify pre-diagnostic epigenetic biomarkers of colorectal cancer risk and understand epigenetic mechanisms of lifestyle and genetic CRC risk factors across multiple U.S. populations. The research will conduct a nested case-control study of 1,500 colorectal cancer cases and 1,500 matched controls drawn from the...
- The National Cancer Institute awarded Cedars-Sinai Medical Center $662,610 on April 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a plasma-based panel of methylated circulating tumor DNA markers for detecting recurrence and predicting therapy response in colorectal cancer patients. The award funds a five-year research collaboration between Cedars-Sinai Medical Center and H. Lee Moffitt Cancer Center and Research Institute to evaluate the...
- The National Cancer Institute awarded a cooperative agreement totaling $738,675 to Beckman Research Institute of the City of Hope on March 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an exosome-based liquid biopsy assay for non-invasive early detection of colorectal adenomas and cancers. The project addresses the limitation that current fecal immunochemical testing (FIT) shows declining sensitivity for early-stage colorectal cancer and advanced...
- The National Cancer Institute awarded The University of Chicago $421,685 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate TET3 cytosine demethylase as a target for enhancing radiotherapy response in mismatch repair-proficient colorectal cancer. The project uses CRISPR loss-of-function models in colorectal cancer cell lines and syngeneic tumors to examine how TET3 disruption affects double-strand break repair kinetics, cytosolic DNA accumulation,...
- The National Cancer Institute awarded the University of Pittsburgh $396,799 on April 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop biomarkers and computational models for predicting adenoma recurrence in patients with advanced adenomas. The project funds evaluation of colorectal lesions using two novel approaches: assessment of aberrant alterations in chromatin structure at nanoscale sensitivity, and spatial analysis of tissue samples. The research...
- The National Cancer Institute awarded MD Anderson Cancer Center a $1.5 million Cooperative Agreement on July 23, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop clinical-grade combinatorial new approach methodologies (NAMs) assays for colorectal cancer treatment decisions. The recipient will validate three core methodologies—in vitro micro-organospheres (MOSs), in silico DL-Reflect, and VirtualCellTherapy—using clinical samples and patient outcomes across...
- The National Cancer Institute awarded the University of California, San Diego $671,226 on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop engineered native bacteria—host-derived E. coli strains—as a microbial platform for durable, targeted delivery of therapeutic molecules to the gut to prevent or treat colorectal cancer. The research addresses a critical gap in microbial therapies for colorectal cancer, which the American Cancer Society projects will account...
- The National Cancer Institute awarded The University of Chicago $388,234 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop sequencing technology for studying small nucleolar RNA (snoRNA) targets and their roles in cancer. The research encompasses two primary aims. Aim 1 will enhance the sensitivity and resolution of snoRNA-enriched kethoxal-assisted RNA-RNA sequencing (SNOKARR-SEQ) to identify low-abundance snoRNA targets in cancer cells using mutation...
- Federal Project Grant Award Summary The University of Chicago received a $372,628 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective September 12, 2025, with completion targeted for August 31, 2028. This award supports research into spatiomolecular profiling of human cancer at scale, specifically focused on developing and advancing spatially resolved transcriptomics (ST) technologies for analyzing tumor...